Published in final edited form as:

Mol Carcinog. 2011 November ; 50(11): 884–900. doi:10.1002/mc.20757.

Functional characterization of peroxisome proliferator-activated receptor- β/δ expression in colon cancer

Jennifer E. Foreman¹, Wen-Chi L. Chang², Prajakta S. Palkar¹, Bokai Zhu¹, Michael G. Borland¹, Jennie L. Williams³, Lance R. Kramer¹, Margie L. Clapper², Frank J. Gonzalez⁴, and Jeffrey M. Peters^{1,*}

¹Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA

²Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA

³Cancer Prevention Laboratory, State University of New York at Stony Brook, Stony Brook, NY

⁴Laboratory of Metabolism, National Cancer Institute, Bethesda, MD

Abstract

This study critically examined the role of PPAR β/δ in colon cancer models. Expression of PPAR β/δ mRNA and protein was lower and expression of CYCLIN D1 protein higher in human colon adenocarcinomas compared to matched non-transformed tissue. Similar results were observed in colon tumors from *Apc*^{+/Min-FCCC} mice compared to control tissue. Dietary administration of sulindac to *Apc*^{+/Min-FCCC} mice had no influence on expression of PPAR β/δ in normal colon tissue or colon tumors. Cleaved poly (ADP-ribose) polymerase (PARP) was either increased or unchanged, while expression of 14-3-3 ϵ was not influenced in human colon cancer cell lines cultured with the PPAR β/δ ligand GW0742 under conditions known to increase apoptosis. While DLD1 cells exhibited fewer early apoptotic cells after ligand activation of PPAR β/δ following treatment with hydrogen peroxide, this change was associated with an increase in late apoptotic/necrotic cells, but not an increase in viable cells. Stable over-expression of PPAR β/δ in human colon cancer cell lines enhanced ligand activation of PPAR β/δ and inhibition of clonogenicity in HT29 cells. These studies are the most quantitative to date to demonstrate that expression of PPAR β/δ is lower in human and *Apc*^{+/Min-FCCC} mouse colon tumors than in corresponding normal tissue, consistent with the finding that increasing expression and activation of PPAR β/δ in human colon cancer cell lines inhibits clonogenicity. Because ligand-induced attenuation of early apoptosis can be associated with more late, apoptotic/necrotic cells, but not more viable cells, these studies illustrate why more comprehensive analysis of PPAR β/δ -dependent modulation of apoptosis is required in the future.

Keywords

apoptosis; clonogenicity; tumorigenicity

INTRODUCTION

Peroxisome proliferator-activated receptor- β/δ (PPAR β/δ) is a ligand activated transcription factor that has critical cellular functions mediated by receptor-dependent modulation of

*To whom correspondence should be addressed: Jeffrey M. Peters, Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, Tel: (814) 863-1387, Fax: (814) 863-1696, jmp21@psu.edu.

target gene expression in addition to epigenetic activities (reviewed in [1–3]). PPAR β/δ is expressed in most tissues, but is expressed at the highest levels in epithelium, in particular skin and intestine [4–8]. Interestingly, in cells where PPAR β/δ is expressed, the receptor is found in the nucleus and can be co-immunoprecipitated with its heterodimerization partner, retinoid X receptor (RXR), suggesting that PPAR β/δ has an important constitutive biological function(s) that is/are possibly mediated by endogenous ligands [6]. The best-characterized role for PPAR β/δ to date is its involvement in the promotion of terminal differentiation in many cell types including epithelium (reviewed in [1–3]). In addition, pre-clinical and clinical trials have demonstrated that ligand activation of PPAR β/δ stimulates potent anti-inflammatory activities [9], increases serum HDL-cholesterol concentrations [10–13], improves exercise endurance [14] and is central in the regulation of lipid and glucose homeostasis [15–17].

In contrast to the established effects of activating PPAR β/δ that are of interest for the treatment and prevention of metabolic diseases including obesity, diabetes and dyslipidemias, the role of PPAR β/δ in cancer remains uncertain. Some studies indicate that PPAR β/δ promotes tumorigenesis while others suggest that PPAR β/δ attenuates tumorigenesis (reviewed in [1–3]). It was originally hypothesized that PPAR β/δ was upregulated by the adenomatous polyposis coli (APC)/ β -CATENIN/transcription factor 4 (TCF4) pathway during colon carcinogenesis and facilitated tumor growth by modulating a group of yet-to-be identified target genes [18]. This idea was based in part on the observed correlation of decreased PPAR β/δ expression and increased APC expression in a human colon cancer cell line and the reported increase in PPAR β/δ expression in four human colon tumors as compared to normal tissue [18]. Since this preliminary report, results from a number of studies that examined expression of PPAR β/δ in human and experimental models of colon cancer have failed to provide support for the view that PPAR β/δ is increased in colon cancer cells or that PPAR β/δ is upregulated by the APC/ β -CATENIN/TCF4 pathway ([19], reviewed in [3]). Some reports have also suggested that the chemopreventive effects of non-steroidal anti-inflammatory drugs (NSAIDs) are mediated in part by reduced expression of PPAR β/δ in colon cancer models, but this result is not observed consistently (reviewed in [2,3]). In fact, in some cases, upregulation of PPAR β/δ is found in human colon cancer cells following treatment with NSAIDs [19]. Several technical limitations are commonly associated with the latter observation including the use of immunohistochemistry to assess expression, a sole focus on mRNA expression, evaluation of a small number of independent samples, and failure to quantify PPAR β/δ expression by western blotting. Thus, whether expression of PPAR β/δ is increased, unchanged, or decreased during colon carcinogenesis remains unclear.

The effect of ligand activation of PPAR β/δ during colon carcinogenesis also remains unclear. There is evidence to suggest that ligand activation of PPAR β/δ promotes cell proliferation during colon tumor formation by regulating unidentified target genes that modulate cell cycle progression (reviewed in [2,3]). It has also been hypothesized that ligand activation of PPAR β/δ prevents apoptosis induced by NSAIDs or hydrogen peroxide in colon cancer cell lines. This hypothesis is based on the idea that PPAR β/δ prevents chemically-induced apoptosis by increasing expression of 14-3-3 ϵ whose elevated levels enhance sequestration of Bad, a pro-apoptotic member of the B-cell CLL/lymphoma 2 (Bcl-2) family [20–23]. In contrast, a large body of literature suggests that ligand activation of PPAR β/δ has either no effect on, or inhibits, colon tumorigenesis by enhancing terminal differentiation and promoting apoptosis (reviewed in [2,3]). These inconsistent results dictate a need to further examine the functional role of PPAR β/δ in colon cancer development.

The present studies were designed to characterize the functional role of PPAR β/δ in colon cancer. Expression of PPAR β/δ was measured at both the protein and mRNA level in colon tissue (tumors and matched control) from cancer patients, and in intestinal tissue from a unique strain of Multiple Intestinal Neoplasia (*Apc*^{+/Min-FCCC}) mice that develop multiple colorectal adenomas [24]. The effect of ligand activation of PPAR β/δ on apoptosis was also examined by flow cytometry of human colon cancer cells following chemically-induced apoptosis. Lastly, the clonogenicity of stable human colon cancer cell lines over-expressing PPAR β/δ was examined.

MATERIALS AND METHODS

Cell Culture

RKO, DLD1 and HT29 were obtained from ATCC. RKO cells were cultured in Dulbecco's modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA). DLD1 cells were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA). HT29 cells were cultured in McCoy's 5A medium (Invitrogen, Carlsbad, CA). All cell lines were cultured in medium with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 °C and 5% carbon dioxide.

Mouse Colon Cancer Model

Male C57BL/6J wild-type or *Apc*^{+/Min-FCCC} [24], aged 6–8 weeks were used for this study. Mice of both genotypes (9 wild-type and 10–12 *Apc*^{+/Min-FCCC} mice) were fed either control diet (Purina Rodent Chow 5013, PMI-Nutrition International, Inc., Brentwood, MO) or diet containing sulindac (300 ppm) for forty-five days. At the time of euthanasia, the colons were excised, flushed with phosphate buffered saline and examined grossly for the presence of tumors. Identifiable tumors were collected while the remaining colonic mucosa was isolated from the tissue by scraping it with a glass slide. All samples were snap frozen for protein and mRNA isolation as described below.

Human Colon Tissue Samples

Matched pairs of frozen normal colon tissue and colon or rectal adenocarcinomas were obtained from The Penn State Hershey Cancer Institute Tissue Bank. A summary of the sample demographics is provided in Table 1. Protein or mRNA was prepared from these samples as described below.

Induction of Apoptosis in Human Colon Cancer Cell Lines

For human colon cancer cell lines, RKO (wild-type APC and β -catenin), DLD1, and HT29 (mutant APC and wild-type β -catenin) cells were cultured on 60 mm dishes and maintained in culture medium as described above, until they were approximately 80% confluent on the day of treatment. Cells were then pretreated for 1 h with either 0.1% DMSO, or the selective PPAR β/δ agonist GW0742 (0.1, 1.0, and 10 μ M) and then treated for 24 h with 800 μ M indomethacin, 150 μ M sulindac, and 160 μ M sulindac sulfide, or 4 h with 0.5 mM hydrogen peroxide in the presence of ligand. The selected concentrations of GW0742 are known to specifically activate PPAR β/δ in these cell lines [19,25]. The concentrations of indomethacin, sulindac and sulindac sulfide were chosen based on previous studies showing inhibition of cell proliferation [19], and PPAR β/δ -dependent attenuation of NSAID-induced apoptosis in the same human colon cancer cell lines [20]. Preliminary analyses from this group indicate that 0.5 mM hydrogen peroxide is the optimal concentration to increase apoptosis sufficiently without causing excessive cell death (data not shown). The same exposure paradigm was used to suggest PPAR β/δ -mediated attenuation of hydrogen peroxide-induced apoptosis in endothelial cells due to suppression of 14-3-3 ϵ [21].

Untreated cells were used as a negative control, while cells treated with only 2 μ M staurosporine for five hours served as a positive control.

Western Blot Analysis

Protein extracts were prepared from the mouse colonic mucosa, tumor samples or human colon cancer cell lines as described previously [6]. Snap frozen human tissue samples were ground to a powder using a mortar and pestle in liquid nitrogen. This ground tissue was used for isolation of protein or mRNA. Whole cell protein extracts were prepared using MENG buffer (25 mM MOPS, 2 mM EDTA, 0.02% NaN₃, and 10% glycerol, pH 7.5) containing 500 mM NaCl, 1% Nonidet P-40, and protease inhibitors. Twenty-five to fifty micrograms of protein per sample was resolved using 10% SDS-polyacrylamide gels and transferred onto a polyvinylidene fluoride membrane using an electroblotting method. Membranes were incubated with primary antibodies, washed, incubated with a biotinylated secondary antibody, washed, and then incubated with ¹²⁵I-streptavidin to allow for detection. Membranes were exposed to plates and the level of radioactivity quantified with filmless autoradiographic analysis. The following primary antibodies were used: anti-14-3-3 ϵ (sc1020; Santa Cruz Biotechnologies, Santa Cruz, CA), anti-PPAR γ (sc6284; Santa Cruz Biotechnologies, Santa Cruz, CA), anti-PPAR β/δ (human) (ab21209; Abcam Inc., Cambridge, MA), anti-PPAR β/δ (mouse) [6], anti-CYCLIN D1 (Cell Signaling Technology, Danvers, MA), anti-PARP (Cell Signaling Technology, Danvers, MA), anti- β -actin (ACTIN; Rockland, Gilbertsville, PA) and anti-lactate dehydrogenase (LDH; Rockland, Gilbertsville, PA). Hybridization signals for the proteins of interest were normalized to the hybridization signal of either ACTIN or LDH. The ratio of normalized cleaved PARP to normalized uncleaved PARP was used as a measure of relative apoptosis.

RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction

Total RNA was isolated from colon tissue, tumor samples or human colon cancer cell lines using Ribozol (Amresco, Solon, OH) according to the manufacturer's protocol. The mRNAs encoding PPAR β/δ , and its target genes adipocyte differentiation-related protein (*ADRP*) and angiopoietin-like protein 4 (*ANGPTL4*) were quantified using quantitative real-time polymerase chain reaction (qPCR). cDNA was generated using 2.5 μ g total RNA with MultiScribe Reverse Transcriptase kit (Applied Biosystems, Foster City, CA). Primers were designed for real-time PCR using the Primer Express software (Applied Biosystems). The sequence and GenBank accession number for the forward and reverse primers used to quantify mRNAs were: human *PPAR β/δ* (AY919140) forward, 5'-GACAGTGACCTGGCCCTATTCA-3' and reverse, 5'-AGGATGGTGTCTGGATAGCCT-3', mouse *PPAR β/δ* (NM_011145) forward, 5'-TTGAGCCCAAGTTCGAGTTTGCTG-3' and reverse, 5'-ATTCTAGAGCCCGCAGAATGGTGT-3', mouse *PPAR γ* (NM_011146) forward, 5'-GACAGTGACCTGGCCCTATTCA-3' and reverse, 5'-AGGATGGTGTCTGGATAGCCT-3', *ADRP* (NM_000122) forward, 5'-CTGCTCTTCGCCTTTCGCT-3', and reverse, 5'-ACCACCCGAGTCACCACACT-3', and *ANGPTL4* (NM_020581) forward, 5'-TTCTCGCTACCAGAGAAGTTGGG-3' and reverse, 5'-CATCCACAGCACCTACAACAGCAC-3'. Expression of mRNA was normalized to *GAPDH* mRNA (BC083149) that was quantified using the following primers: forward, 5'-GGTGGAGCCAAAAGGGTCAT-3' and reverse, 5'-GGTTCACACCCATCACAACAT-3'. Real-time PCR reactions were carried out using SYBR green PCR master mix (Finnzymes, Espoo, Finland) in the iCycler and detected using the MyiQ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). The following conditions were used for PCR: 95 °C for 15 s, 94 °C for 10 s, 60 °C for 30 s, and 72 °C for 30 s and repeated for 45 cycles. The PCR included a no template reaction to control for contamination and/or genomic amplification. All reactions had >85% efficiency.

To control for interindividual variability in PPAR β/δ expression, the ratio of normalized PPAR β/δ mRNA for each tumor relative to normalized PPAR β/δ mRNA of each matched control was calculated. This type of analysis creates a positively skewed data distribution, giving a greater range of values for those samples that exhibit higher expression of PPAR β/δ mRNA in the tumor as compared to the matched control ($1 - \infty$) in comparison to samples that exhibit lower expression of PPAR β/δ mRNA in the tumor as compared to the matched control ($0 - 1$). To control for the skew associated with this type of analysis, the data was log 2 transformed to make a symmetrical data distribution centered around zero. This gives a normal distribution and allows for statistical analyses [26–28].

Examination of Apoptosis and Cell Viability by Flow Cytometry

RKO, DLD1, or HT29 cells were plated on 24-well dishes and cultured as described above until they were approximately 80% confluent on the day of treatment. Cells were pretreated for 1 h with either 0.02% DMSO, or GW0742 (0.1, 1.0, and 10 μ M) and then treated for either 4 h in 0.0, 0.5 or 5.0 mM hydrogen peroxide in the presence or absence of GW0742 (0.1, 1.0, and 10 μ M). After these treatments, culture medium was removed and the cells were trypsinized, pelleted and resuspended in annexin V binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl₂). Prior to analysis, the cells were incubated with a FITC-labeled anti-annexin V antibody for 15 min after which propidium iodide (PI, 1 μ g/ μ L) was added to each sample. Approximately 10,000 cells/sample were analyzed using an EPICS-XL-MCL flow cytometer (Beckman Coulter, Miami Lakes, FL) fitted with a single 15-mW argon ion laser (excitation at 488 nm). Cells stained with FITC were monitored through a 525 nm bandpass filter. Viable cells were defined as the percentage of cells that were annexin V-negative and PI-negative. Early apoptosis was defined as the percentage of cells that were annexin V-positive and PI-negative, and late apoptosis/necrosis was defined as the percentage of cells that were annexin V-negative and PI-positive or annexin V-positive and PI-positive. Values were calculated from a minimum of three independent samples per treatment.

Generation of Stable Cell Lines Over-Expressing PPAR β/δ

The pMigr1 vector (Migr1) and pCL-Ampho have been previously described [29]. The Migr1 retroviral vector contains the mouse stem cell virus promoter that drives expression of cDNA cloned into a cloning site, followed by an internal ribosome entry site (IRES) and a sequence encoding enhanced green fluorescent protein (eGFP) [29]. This bi-cistronic vector allows for expression of a protein of interest and eGFP, which facilitates identification and sorting of cells that have stably integrated the Migr1 retroviral vector. The pcDNA3.1-hPPAR β/δ construct was kindly provided by Dr. Curt Omiecinski (The Pennsylvania State University, University Park, PA). The Migr1-hPPAR β/δ vector was made by subcloning the human PPAR β/δ cDNA sequence from pcDNA3.1-hPPAR β/δ into the Migr1 vector. The coding sequence was confirmed by sequencing at the Penn State University Nucleic Acid Facility. Stable Migr1 (vector control) and Migr1-hPPAR β/δ cell lines were established by retrovirus spinoculation as described previously [29]. Briefly, each construct and pCL-Ampho plasmids were co-transfected into HEK293T cells to produce retrovirus using the Lipofectamine® transfection reagent and the manufacturer's recommended protocol. Forty-eight hours after transfection, the supernatant containing the retrovirus was passed through a 0.22 μ m filter and used to spinoculate RKO, DLD1 or HT29 cells. eGFP-positive cells were isolated by fluorescence-activated cell sorting using an InFlux V-GS Cytometry Workbench and Spigot software (BD Biosciences, San Jose, CA). Forward-scatter and side-scatter dot plots gave the cellular physical properties of size and granularity and allowed gating for live cells. Fluorescence was excited at 488 nm (eGFP), and emission was collected using a 525 nm band-pass filter. Collected eGFP cells possessed a minimum of 100-fold higher eGFP expression than non-GFP cells. Fluorescence photomicrographs were obtained with a SPOT

SP100 cooled CCD camera fitted to a Nikon Eclipse TE300 upright microscope with EFD-3 episcopic fluorescence attachment. The presence of eGFP fluorescence was routinely checked using the Nikon fluorescence microscope.

Colony Formation Assay

Control (parent human colon cancer cell line, RKO, DLD1 or HT29), cells stably expressing the Migr1-empty vector, or cells stably expressing PPAR β/δ were plated in 60 mm culture dishes. RKO cells were plated at a concentration of 300 cells/well and allowed to adhere for 24 h before treatment. DLD1 and HT29 cells were plated at a concentration of 400 or 600 cells/well, respectively, and allowed to adhere for 8 h before treatment. Adhered cells were treated with medium containing either: 0 (DMSO control), 0.1, 1.0 or 10 μ M GW0742. RKO, DLD1 and HT29 cells were cultured for 14, 13 or 15 days, respectively, after which the cell colonies were fixed with 6% (v/v) glutaraldehyde and stained with 0.5% (w/v) crystal violet. Colony number was quantified using Image J software (version 1.37, National Institutes of Health, Bethesda, MD). The plating efficiency and surviving fraction were calculated as described previously [30,31].

Statistical Analysis

Statistical significance was determined using either a t-test or, where applicable, analysis of variance and the Bonferroni post-test (Prism 5.0, GraphPad Software Inc., La Jolla, CA).

RESULTS

PPAR β/δ expression is lower in human colon adenocarcinomas as compared to control tissue

Expression of PPAR β/δ protein was markedly lower in nineteen human colon adenocarcinomas as compared to control colon tissue (Figure 1A, Supplemental Figure 1A). In contrast, expression of CYCLIN D1 was higher in human colon adenocarcinomas as compared to control colon tissue (Figure 1A, Supplemental Figure 1A). Expression of PPAR γ 1 protein was not different in human colon adenocarcinomas as compared to control colon tissue (Figure 1A). No significant difference was found in expression of PPAR β/δ or PPAR γ 1 protein in human rectal adenocarcinomas as compared to control tissue, and while expression of CYCLIN D1 was higher in some human rectal adenocarcinomas, this was not statistically significant (Figure 1A, Supplemental Figure 1A). No difference in relative expression of PPAR β/δ or PPAR γ 1 was observed between male and female samples in either colon adenocarcinomas or rectal adenocarcinomas as compared to control colon (data not shown). Expression of *PPAR β/δ* mRNA between control tissue and both colon and rectal tumors was not different when normalized expression was compared between control tissue *PPAR β/δ* mRNA and both colon and rectal *PPAR β/δ* mRNA, respectively (Figure 1B). Similarly, average expression of *PPAR β/δ* mRNA in only colon or rectal tumor types was not different as compared to expression of *PPAR β/δ* mRNA in control tissue, respectively (Figure 1B). However, the log 2 transformed ratio of normalized *PPAR β/δ* mRNA for each tumor relative to normalized *PPAR β/δ* mRNA of each matched control indicates that average expression of *PPAR β/δ* mRNA is lower in colon adenocarcinomas as compared to matched control tissue from each sample (Figure 1C).

PPAR β/δ expression is lower in *Apc*^{+/Min-FCCC} mouse colon tumors as compared to control tissue

Expression of PPAR β/δ in colon tumors was also examined in the *Apc*^{+/Min-FCCC} mouse model. Additionally, the effect of feeding a diet containing sulindac was also determined because previous studies suggest that treatment with NSAIDs inhibits expression of PPAR β/δ .

δ in human colon cancer cell lines [20,32,33]. Average colon tumor multiplicity was 6.3 ± 0.8 in control *Apc*^{+/Min-FCCC} mice and 4.3 ± 0.8 in *Apc*^{+/Min-FCCC} mice fed sulindac ($P=0.057$). PPAR β/δ protein was markedly lower (~60%), and expression of CYCLIN D1 was markedly higher (~400%) in control *Apc*^{+/Min-FCCC} mouse colon tumors as compared to control colon mucosa (Figure 2A, Supplemental Figure 1B). Similarly, expression of PPAR γ 1 was markedly lower (~70%) in colon tumors as compared to colon mucosa in *Apc*^{+/Min-FCCC} mice (Figure 2A). Similar changes in PPAR β/δ , PPAR γ 1 and CYCLIN D1 were observed in *Apc*^{+/Min-FCCC} mouse colon tumors following treatment with dietary sulindac as compared to sulindac-treated colon mucosa (Figure 2A, Supplemental Figure 1B). The expression pattern of *Ppar β/δ* and *Ppar γ* mRNA (Figure 2B) closely paralleled the observed decrease in PPAR β/δ and PPAR γ 1 protein expression found in colon tumors from *Apc*^{+/Min-FCCC} mice (Figure 2A). Expression of *Ppar β/δ* and *Ppar γ* mRNA was lower in colon tumors from *Apc*^{+/Min-FCCC} mice fed either the control or sulindac diet (Figure 2B). Interestingly, while protein expression of PPAR β/δ was not different in colon mucosa from *Apc*^{+/Min-FCCC} mice fed sulindac as compared to colon mucosa from *Apc*^{+/Min-FCCC} mice fed the control diet, expression of *Ppar β/δ* mRNA was higher in colon mucosa from *Apc*^{+/Min-FCCC} mice fed sulindac as compared to colon mucosa from *Apc*^{+/Min-FCCC} mice fed the control diet (Figure 2B).

Effect of Ligand Activation of PPAR β/δ on NSAID or Hydrogen Peroxide-Induced Apoptosis

Previous studies suggest that one mechanism by which NSAIDs inhibit colon cancer cell proliferation is through decreasing expression of PPAR β/δ resulting in increased apoptosis, possibly mediated by PPAR β/δ -dependent down-regulation of 14-3-3 ϵ [20,32,33]. Similarly, it was suggested that ligand activation of PPAR β/δ results in anti-apoptotic activity via direct up-regulation of 14-3-3 ϵ [21]. These hypothetical mechanisms were critically evaluated in the present study using the same human colon cancer cell lines and concentrations of NSAIDs by examining quantitative expression of PPAR β/δ and 14-3-3 ϵ , cleavage of PARP, and quantification of annexin V-positive cells using flow cytometry. In contrast to previous studies [20,32,33], expression of PPAR β/δ was either unchanged or increased in RKO, DLD1 or HT29 cells treated with indomethacin, sulindac, sulindac sulfide or hydrogen peroxide as compared to controls not treated with the indomethacin, sulindac, sulindac sulfide or hydrogen peroxide (Supplemental Figure 2). Expression of PPAR β/δ was unchanged in DLD1 cells following treatment with indomethacin or sulindac sulfide, with and without co-treatment with GW0742 as compared to controls not treated with the NSAIDs (Supplemental Figure 2). Expression of PPAR β/δ was also unchanged in RKO, DLD1 and HT29 cells following treatment with hydrogen peroxide, with and without co-treatment with GW0742 as compared to controls not treated with the hydrogen peroxide (Supplemental Figure 2). In contrast, expression of PPAR β/δ was increased in RKO and HT29 cells treated with indomethacin or sulindac sulfide, and in RKO, DLD1 and HT29 cells treated with sulindac; with and without co-treatment with GW0742 as compared to controls not treated with the NSAIDs (Supplemental Figure 2). Increased cleavage of PARP was observed in RKO and DLD1 cells, but not in HT29 cells, cultured with indomethacin and sulindac sulfide, as compared to controls (Figure 3, Supplemental Fig. 3). A significant increase in PARP cleavage was observed in DLD1 cells co-treated with indomethacin and GW0742 (0.1–10 μ M) as compared to control DLD1 cells cultured with only indomethacin (Figure 3, Supplemental Fig. 3). A similar effect was also observed in DLD1 cells co-cultured with indomethacin and another PPAR β/δ ligand GW501516 (Supplemental Figure 4). While ligand activation of PPAR β/δ with GW0742 did not influence PARP cleavage in HT29 cells co-treated with sulindac sulfide, an increase in PARP cleavage was observed in RKO cells co-treated with sulindac sulfide and GW0742 (1.0 and 10 μ M) and in DLD1 cells co-treated with sulindac sulfide and GW0742 (0.1 and 10 μ M) (Figure 3, Supplemental Fig.

3). Hydrogen peroxide (0.5 mM) did not cause a large increase in cleavage of PARP in RKO, DLD1 or HT29 cells as compared to controls, and co-treatment with GW0742 and hydrogen peroxide had no influence on PARP cleavage in any of the human colon cancer cell lines evaluated (Figure 3, Supplemental Fig. 3). Expression of 14-3-3 ϵ was not influenced by treatment with any NSAID, hydrogen peroxide, GW0742 or co-treatments, except for RKO cells co-treated with hydrogen peroxide and 10 μ M GW0742, where a significant increase was observed (Figure 3).

Since PARP cleavage reflects later stages of apoptosis, earlier stages of apoptosis were examined by quantifying the presence of annexin V by flow cytometry. For this analysis, hydrogen peroxide was used because it can effectively increase apoptotic signaling after acute exposure. Based on exploratory experiments, it was determined that a reasonable range of apoptosis could be achieved by treating the three different cell lines with hydrogen peroxide at a concentration of either 0.5 or 5.0 mM for 4 hours (data not shown). RKO cells were relatively resistant to hydrogen peroxide-induced apoptosis. While the percentage of cells undergoing late apoptosis/necrosis was marginally higher and the percentage of viable cells was marginally lower in RKO cells treated with 5.0 mM hydrogen peroxide for 4 h as compared to controls, these trends were not statistically significant (Figure 4A). Ligand activation of PPAR β/δ in RKO cells treated with hydrogen peroxide did not influence the percentage of cells undergoing apoptosis in response to either 0.5 or 5.0 mM hydrogen peroxide (Figure 4A). In DLD1 cells, 0.5 mM and 5.0 mM hydrogen peroxide caused an increase in the percentage of cells undergoing late apoptosis/necrosis that was associated with a decrease in viable cells compared to untreated control DLD1 cells (Figure 4B). Ligand activation of PPAR β/δ in DLD1 cells caused a decrease in the percentage of cells undergoing early apoptosis in control cells and this effect was also observed in cells co-treated with 0.5 mM hydrogen peroxide and GW0742 (Figure 4B). However, these changes were reflected by an increase in cells undergoing late apoptosis/necrosis and a decrease in the percentage of viable cells (Figure 4B). Hydrogen peroxide exposure caused a dose dependent increase in the percentage of HT29 cells undergoing late apoptosis/necrosis and this was associated with a lower percentage of viable cells (Figure 4C). Co-treatment with hydrogen peroxide and GW0742 only caused an increase in the percentage of cells undergoing late apoptosis/necrosis (Figure 4C). Most notably, co-treatment of 5.0 mM hydrogen peroxide and 10 μ M GW0742 in HT29 cells caused an increase in the percentage of early and late apoptotic/necrotic cells and a decrease in viable cells (Figure 4C).

Stable Over-Expression of PPAR β/δ Enhances Sensitivity to Ligand Activation and Inhibition of Clonogenicity

Since expression of PPAR β/δ protein is quantitatively lower in human colon adenocarcinomas and mouse colon tumors, the effect of over-expression of PPAR β/δ in human colon cancer cell lines was examined. The Migr1 expression vector was used for this purpose. This system allows for isolation of cells stably expressing PPAR β/δ because the bi-cistronic vector allows for expression of not only the protein of interest (e.g. PPAR β/δ) but also eGFP; the latter of which allows for efficient sorting. Indeed, high expression of eGFP is observed in RKO, DLD1 or HT29 cells that have stably integrated the Migr1 vector alone, or Migr1-hPPAR β/δ , while eGFP expression is lacking in the parent cell lines (Figure 5A). Expression of PPAR β/δ is also increased in RKO, DLD1 and HT29 cells that have stably integrated Migr1-hPPAR β/δ , as compared to control cells with the Migr1 vector alone or the parent cell line (Figure 5B). To determine whether the increase in PPAR β/δ expression was functional, the effect of ligand activation on target gene expression was examined. For this purpose, expression of *ADRP* was measured in RKO and *ANGPTL4* in DLD1 cells because previous work demonstrated that these genes were more responsive in these cell lines, respectively [19]. The increase in PPAR β/δ expression observed in human colon cancer cell

lines that had stably integrated Migr1-hPPAR β/δ correlates well with increased efficacy of target gene induction in response to ligand activation of PPAR β/δ in RKO and DLD1 cells (Figure 5C). The efficacy of target gene induction in response to ligand activation of PPAR β/δ in HT29 cells that had stably integrated Migr1-hPPAR β/δ was only comparable to the efficacy observed in the parent HT29 cells (Figure 5C); however, it is worth noting that relative expression of Migr1-hPPAR β/δ was somewhat lower in HT29 cells as compared to RKO and DLD1 cells (Figure 5B).

Based on the known correlation between clonogenicity and in vivo tumorigenesis, colony formation assays were performed. Relative clonogenicity was inhibited in parent RKO cells in response to ligand activation of PPAR β/δ by treatment with either 0.01 or 1.0 μ M GW0742 (Figure 6). Comparable inhibition of clonogenicity was also observed in RKO cells with stable integration of Migr1 or Migr1-hPPAR β/δ , cultured in medium containing between 0.01 and 10 μ M GW0742 (Figure 6). Relative clonogenicity was inhibited in parent DLD1 cells in response to ligand activation of PPAR β/δ by treatment with 10 μ M GW0742 (Figure 7) but no inhibition of clonogenicity was observed in DLD1 cells with stable integration of Migr1 or Migr1-hPPAR β/δ cultured in medium containing between 0.01 and 10 μ M GW0742 (Figure 7). Relative clonogenicity was not changed in parent HT29 cells in response to ligand activation of PPAR β/δ by treatment with 0.01 to 10 μ M GW0742 (Figure 8). Inhibition of clonogenicity was observed in HT29 cells with stable integration of Migr1 following treatment with only 10 μ M GW0742 (Figure 8). Moreover, clonogenicity was inhibited in HT29 cells with stable integration of Migr1-hPPAR β/δ , cultured in medium containing between 0.01 and 10 μ M GW0742 (Figure 8). Similar inhibition of clonogenicity was observed in HT29 cells with stable integration of Migr1-hPPAR β/δ , cultured in medium containing 0.1 μ M GW501516 (Supplemental Figure 5).

DISCUSSION

The present studies were undertaken to focus on several fundamental questions that remain concerning the functional role of PPAR β/δ in colon carcinogenesis. The first question addressed was whether expression of PPAR β/δ is altered in human and/or rodent colon tumors. It was originally hypothesized that expression of PPAR β/δ is directly up-regulated by the APC/ β -CATENIN/TCF4 pathway, similar to that observed for CYCLIN D1 and c-MYC [18]. While increased expression of PPAR β/δ in colon tumors has also been reported by other laboratories, the weight of evidence indicating that PPAR β/δ expression is not up-regulated by the APC/ β -CATENIN/TCF4 pathway is increasing (reviewed in [2,3]). For example, expression of PPAR β/δ is not increased in human colon cancer cell lines with gain-of-function mutations in the APC/ β -CATENIN/TCF4 pathway, despite clear up-regulation of expression of CYCLIN D1 and/or c-MYC [19]. To date, no studies have quantitatively examined expression of PPAR β/δ protein from cohorts of tumors and corresponding control tissue from human colon cancer patients. Thus, results from the present study are the first to demonstrate that expression of PPAR β/δ protein is lower in nineteen human colon adenocarcinomas as compared to matched control colon tissue. It is also important to note that this decrease in colon adenocarcinoma PPAR β/δ was associated with increased expression of CYCLIN D1. The decrease in expression of PPAR β/δ was specific for colon adenocarcinomas as similar changes were not found in a cohort of human rectal tumors. The observed decrease in PPAR β/δ expression in nine colon tumors from *Apc*^{+/Min}-FCCC mice as compared to matched control colon mucosa is also highly consistent with the changes observed in human colon adenocarcinomas, as decreased expression of PPAR β/δ was also associated with markedly higher expression of CYCLIN D1. While previous work showed no change in expression of PPAR β/δ expression in small intestine tumors from *Apc*^{+/Min} mice [19], it is important to note that the present study examined expression from colon tumors from *Apc*^{+/Min} mice and that whole cell lysates were used

rather than nuclear fractions. Collectively, this is the most robust data set published to date that definitively demonstrates that expression of PPAR β/δ protein is decreased, not increased, during colon tumorigenesis.

Most studies to date examining expression of PPAR β/δ during colon carcinogenesis have focused primarily on PPAR β/δ mRNA expression. Previous studies suggesting that expression of PPAR β/δ is increased during colon tumorigenesis are often limited because expression of protein is not compared with that of mRNA (reviewed in [2,3]). Additionally, some studies suggesting increased expression of PPAR β/δ during colon tumorigenesis are limited to immunohistochemical analysis [34,35]. This is problematic because immunohistochemical analysis of PPAR β/δ expression is unreliable due to considerable non-specific immunoreactivity of PPAR β/δ antibodies. For example, while one study suggested that expression of nuclear PPAR β/δ is higher in mouse colon tumors based on immunohistochemical analysis [34], subsequent western blot analysis using samples from the same study revealed no changes in nuclear expression of PPAR β/δ [19]. The hypothesis that expression of PPAR β/δ is increased during colon tumorigenesis as suggested by some (reviewed in [2,3]) is also at odds with the findings that colon and small intestine exhibit the highest expression of PPAR β/δ in mice [6]. Further, recent evidence from antibody proteomic analysis indicates that while expression of PPAR β/δ is strong in human colon cells, expression of PPAR β/δ is weak to negligible in human colorectal cancer [4,8]. Since there is considerable debate whether expression of PPAR β/δ is either increased or decreased during colon tumorigenesis, it is surprising that many reports fail to point out findings reporting that PPAR β/δ is not increased during colon carcinogenesis. Based on the definitive findings from the present work, it is clear that future studies should rigorously examine expression of PPAR β/δ protein to confirm changes in mRNA expression.

It is also of interest to note that expression of PPAR γ 1, was markedly lower in colon tumors from *Apc^{+/Min}-FCCC* mice, but not in human colon or rectal adenocarcinomas. Similar results have also been observed in small intestine polyps from *Apc^{+/Min}* mice [19]. Additionally, decreased PPAR γ mRNA was also reported to occur in colon polyps from azoxymethane-treated mice that correlated with reduced protein expression based on immunohistochemical analysis [36]. In contrast, other studies reported no change in expression of PPAR γ in *Apc^{+/Min}* mice [37,38] or even increased expression of PPAR γ in colon polyps from azoxymethane-treated rats or *Apc^{+/Min}* mice [39–41]. The reason for these differences cannot be determined from the present work. The reason why decreased expression of PPAR γ 1 was not found in human colon or rectal tumors in the present study is also uncertain. While one study showed no difference in expression of PPAR γ mRNA between colonic epithelial cells and tubular adenomas [42], decreased PPAR γ mRNA has been found in colon tumors from acromegalic patients [43,44]. Further studies are necessary to determine why colon tumors from *Apc^{+/Min}-FCCC* mice exhibit decreased expression of PPAR γ 1 while human colon and rectal tumors do not.

The second issue addressed by the present study is whether NSAIDs down-regulate expression of PPAR β/δ during colon carcinogenesis, which in turn promotes apoptotic signaling. This notion is based on the hypothesis that PPAR β/δ is anti-apoptotic and prevents NSAID-induced apoptosis by increasing expression of the 14-3-3 ϵ that enhances sequestration of Bad, a pro-apoptotic member of the B-cell CLL/lymphoma 2 (Bcl-2) family [20,21,23]. This hypothesis is based on studies using human colon cancer cell lines (DLD1 and HT29) and endothelial cells treated with NSAIDs (sulindac sulfide, indomethacin) or hydrogen peroxide to induce apoptosis. Thus, the present study used the same human colon cancer cell lines and the same concentrations of NSAIDs to critically examine the hypothesis that NSAID- or hydrogen peroxide-induced apoptosis is mediated by down-regulation of PPAR β/δ due to decreased expression of 14-3-3 ϵ that leads to increased

apoptosis. In contrast to several reports [20,21,23], results from the present study demonstrate that NSAIDs (sulindac, sulindac sulfide, indomethacin) do not decrease expression of PPAR β/δ , but rather, expression of PPAR β/δ is either unchanged or increased by these drugs. This observation is consistent with a number of other studies (reviewed in [2,3]) including the recent observation that indomethacin increases expression and function of PPAR β/δ in RKO human colon cancer cell lines [19]. Additionally, *in vivo* analyses reveal that nimesulide does not alter expression of PPAR β/δ in the mouse colon [45], and that sulindac does not alter expression of PPAR β/δ in the colon or colon tumors from *Apc^{+/Min}-FCCC* mice as shown from the present studies. While expression of 14-3-3e was increased in RKO cells co-treated with hydrogen peroxide and 10 μ M GW0742, this change in expression was not associated with anti-apoptotic activity, and no changes in 14-3-3e were observed in all other treatment paradigms. Collectively, these observations suggest that NSAIDs do not down-regulate expression of PPAR β/δ in colon cancer models and emphasizes the need to critically examine the hypothesis that PPAR β/δ is anti-apoptotic and prevents NSAID-induced apoptosis by increasing expression of the 14-3-3e that enhances sequestration of Bad as suggested by others [20,21,23].

Since NSAIDs do not down-regulate PPAR β/δ expression in either human colon cancer cell lines or colon tumors from *Apc^{+/Min}-FCCC* mice, it is not surprising that ligand activation of PPAR β/δ did not attenuate PARP cleavage following treatment with either sulindac, sulindac sulfide, indomethacin or hydrogen peroxide. In fact, the only change observed in PARP cleavage was that co-treatment of NSAIDs with GW0742 enhanced PARP cleavage in DLD1 and RKO cells. These findings demonstrate that ligand activation can promote apoptosis in human colon cancer cells when combined with indomethacin or sulindac sulfide, rather than attenuate apoptosis as suggested by others (reviewed in [2,3]). It is thus noteworthy that a dose-dependent decrease in the percentage of DLD1 cells undergoing early apoptosis was observed in response to ligand activation of PPAR β/δ following induction of apoptosis with hydrogen peroxide. This is important to note, because this change was associated with a concomitant increase in the percentage of cells undergoing late apoptosis/necrosis and a decrease in the percentage of viable cells. These observations might explain why others suggest that PPAR β/δ promotes anti-apoptotic activities, when in fact, this change is associated with more cells that have already undergone apoptosis/necrosis, but not with more viable cells. This also illustrates the need for future studies to comprehensively examine the effect of PPAR β/δ on apoptosis, including examination of different stages of apoptosis and cell viability.

The effect of increasing expression of PPAR β/δ in human colon cancer cells was the last important issue examined by the present study. Whether PPAR β/δ promotes or attenuates colon tumorigenesis remains uncertain. Results from the present study showing markedly lower expression of PPAR β/δ in both human colon adenocarcinomas and colon tumors from *Apc^{+/Min}-FCCC* mice suggest that increasing expression of PPAR β/δ will attenuate colon tumorigenesis. Indeed, PPAR β/δ attenuation of colon tumorigenesis has been observed in some null mouse models [45–47], but not all [48,49]. Similarly, knockdown of PPAR β/δ in HCT116 human colon cancer cells is reported to increase cell proliferation in one model [50], but prevent xenograft tumorigenesis in another [51]. Thus, examination of PPAR β/δ over-expression is an alternative approach to those that have been used previously to examine the role of PPAR β/δ expression in colon carcinogenesis. Over-expression of PPAR β/δ in RKO and DLD1 cells increased the efficacy of ligand activation as target gene expression is enhanced in cells over-expressing PPAR β/δ as compared to control cells. Why enhanced target gene expression in HT29 cells over-expressing PPAR β/δ compared to control was not observed cannot be determined from this work, but could be due to differences in the presence of co-activators, co-repressors or other accessory proteins (e.g. RXR), epigenetic differences in the promoter regions of PPAR β/δ target genes, to the fact

that HT29 cells have two mutant copies of the APC allele and/or to differences related to site(s) of integration of the retroviral vector. Ligand activation of PPAR β/δ inhibited clonogenicity in RKO cells, but over-expression of PPAR β/δ did not markedly enhance this effect. Ligand activation of PPAR β/δ with GW0742 inhibited clonogenicity in DLD1 cells, but only at a concentration of 10 μ M. No change in clonogenicity was found in either Migr1-control DLD1 cells or in DLD1 cells over-expressing PPAR β/δ in response to ligand activation of PPAR β/δ . The lack of an enhanced effect in cells with stable integration of either Migr1 or Migr1-hPPAR β/δ suggests that the Migr1 vector contributes to this phenotype. Interestingly, despite the lack of enhanced efficacy on target gene expression, over-expression of PPAR β/δ caused enhanced inhibition of clonogenicity in HT29 cells as compared to control HT29 cells. The reason why enhanced inhibition of clonogenicity was only observed in HT29 cells that modestly over-expressed PPAR β/δ and co-treated with the highly specific PPAR β/δ GW0742, but not in control HT29 cells treated with GW0742, is unclear. This could be due to differences in the ability of PPAR β/δ to alter gene expression and function in the different cell lines through undefined mechanisms. The inhibition of clonogenicity suggests that the observed decrease in expression of PPAR β/δ found in human colon adenocarcinomas could be causally related to colon tumor progression, and that restoring or activating PPAR β/δ may be a suitable target for preventing colon tumorigenesis. This is consistent with previous work showing PPAR β/δ -dependent inhibition of colon tumorigenicity following ligand activation of PPAR β/δ in mice [45–47]. Importantly, in the presence of increased expression of PPAR β/δ , human colon cancer cell line clonogenicity is either unaffected or is inhibited further in response to ligand activation of PPAR β/δ . No increase in clonogenicity was observed in any of the three different models.

Combined, the results from these studies significantly advance the field because they are the first to provide quantitative evidence from both human and mouse models of colon cancer demonstrating that expression of PPAR β/δ is lower during colon tumorigenesis. These findings increase the body of evidence supporting the hypothesis that activating PPAR β/δ prevents colon tumorigenesis. The reason(s) why some studies suggest that PPAR β/δ promotes tumorigenesis through a variety of unconfirmed mechanisms remain unclear. However, given the findings from the present studies, future work should include definitive examination of PPAR β/δ expression, and not rely on past reports to suggest increased expression of PPAR β/δ during colon tumorigenesis. Results from the present study also emphasize that comprehensive analysis of apoptosis including cytometric analysis of viable and apoptotic cells are recommended. Finally, there remains a need for more fundamental research on the role of PPAR β/δ in colon cancer to help resolve conflicting reports in the literature.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge Drs. Andrew Billin and Timothy Willson for providing the GW0742, Elaine Kunze, Susan Magargee, and Nicole Bem from the Center for Quantitative Cell Analysis at the Huck Institutes of Life Sciences of The Pennsylvania State University for their technical support with flow cytometry and data analysis, and Daniel Beard from the Penn State Hershey Cancer Institute Tissue Bank for providing the human tissue samples, and the Laboratory Animal Facility and the Genomics Facility at Fox Chase Cancer Center. This work was supported in part by CA97999, CA124533, CA126826, CA141029, CA 140369 (JMP), CA006927 and CA129467 (MLC) and CA140487 (JLW).

Abbreviations

ADRP	adipocyte differentiation-related protein
ANGPTL4	angiopoietin-like protein 4
APC	adenomatous polyposis coli
BCL-2	B-cell CLL/lymphoma 2l
NSAID	non-steroidal anti-inflammatory drugs
PARP	poly (ADP-ribose) polymerase
PPAR	peroxisome proliferator-activated receptor
RXR	retinoid X receptor
TCF4	transcription factor 4

References

1. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM. The role of peroxisome proliferator-activated receptor- β/δ in epithelial cell growth and differentiation. *Cell Signal*. 2006; 18(1):9–20. [PubMed: 16109478]
2. Peters JM, Gonzalez FJ. Sorting out the functional role(s) of peroxisome proliferator-activated receptor- β/δ (PPAR β/δ) in cell proliferation and cancer. *Biochim Biophys Acta*. 2009; 1796(2): 230–241. [PubMed: 19505534]
3. Peters JM, Hollingshead HE, Gonzalez FJ. Role of peroxisome-proliferator-activated receptor β/δ (PPAR β/δ) in gastrointestinal tract function and disease. *Clin Sci (Lond)*. 2008; 115(4):107–127. [PubMed: 18616431]
4. Berglund L, Bjorling E, Oksvold P, et al. A gene-centric Human Protein Atlas for expression profiles based on antibodies. *Mol Cell Proteomics*. 2008; 7(10):2019–2027. [PubMed: 18669619]
5. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. *Endocrinology*. 2001; 142(10): 4195–4202. [PubMed: 11564675]
6. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM. Quantitative expression patterns of peroxisome proliferator-activated receptor- β/δ (PPAR β/δ) protein in mice. *Biochem Biophys Res Commun*. 2008; 371(3):456–461. [PubMed: 18442472]
7. Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. *Proc Natl Acad Sci U S A*. 1994; 91(15):7355–7359. [PubMed: 8041794]
8. Uhlen M, Bjorling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. *Mol Cell Proteomics*. 2005; 4(12):1920–1932. [PubMed: 16127175]
9. Kilgore KS, Billin AN. PPAR β/δ ligands as modulators of the inflammatory response. *Curr Opin Investig Drugs*. 2008; 9(5):463–469.
10. Briand F, Naik SU, Fuki I, et al. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. *Clin Transl Sci*. 2009; 2(2):127–133. [PubMed: 20169010]
11. Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPAR δ alters lipid metabolism in db/db mice. *FEBS Lett*. 2000; 473(3):333–336. [PubMed: 10818235]
12. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. *Proc Natl Acad Sci U S A*. 2001; 98(9):5306–5311. [PubMed: 11309497]
13. Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. *Arterioscler Thromb Vasc Biol*. 2007; 27(2):359–365. [PubMed: 17110604]

14. Narkar VA, Downes M, Yu RT, et al. AMPK and PPAR δ agonists are exercise mimetics. *Cell*. 2008; 134(3):405–415. [PubMed: 18674809]
15. Grimaldi PA. Metabolic and nonmetabolic regulatory functions of peroxisome proliferator-activated receptor β . *Curr Opin Lipidol*. 2010; 21(3):186–191. [PubMed: 20480546]
16. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. *Endocrinology*. 2003; 144(6):2201–2207. [PubMed: 12746275]
17. Lee CH, Olson P, Hevener A, et al. PPAR δ regulates glucose metabolism and insulin sensitivity. *Proc Natl Acad Sci U S A*. 2006; 103(9):3444–3449. [PubMed: 16492734]
18. He TC, Chan TA, Vogelstein B, Kinzler KW. PPAR δ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. *Cell*. 1999; 99(3):335–345. [PubMed: 10555149]
19. Foreman JE, Sorg JM, McGinnis KS, et al. Regulation of peroxisome proliferator-activated receptor- β/δ by the APC/ β -CATENIN pathway and nonsteroidal antiinflammatory drugs. *Mol Carcinog*. 2009; 48(10):942–952. [PubMed: 19415698]
20. Liou JY, Ghelani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14–3–3 ϵ . *Cancer Res*. 2007; 67(7):3185–3191. [PubMed: 17409426]
21. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor- δ mediated 14–3–3 upregulation. *Arterioscler Thromb Vasc Biol*. 2006; 26(7):1481–1487. [PubMed: 16645156]
22. Liou JY, Wu CC, Chen BR, Yen LB, Wu KK. Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor- δ transcriptional pathway. *Mol Pharmacol*. 2008; 74(5):1399–1406. [PubMed: 18678619]
23. Wu KK, Liou JY. Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPAR δ --> 14–3–3 ϵ pathway. *Methods in molecular biology* (Clifton, NJ). 2009; 512:295–307.
24. Cooper HS, Chang WC, Coudry R, et al. Generation of a unique strain of multiple intestinal neoplasia (Apc(+/-Min-FCCC)) mice with significantly increased numbers of colorectal adenomas. *Mol Carcinog*. 2005; 44(1):31–41. [PubMed: 15937958]
25. Hollingshead HE, Killins RL, Borland MG, et al. Peroxisome proliferator-activated receptor- β/δ (PPAR β/δ) ligands do not potentiate growth of human cancer cell lines. *Carcinogenesis*. 2007; 28(12):2641–2649. [PubMed: 17693664]
26. Ferris FL 3rd, Miller KM, Glassman AR, Beck RW. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. *Ophthalmology*. 2010; 117(8):1512–1516. [PubMed: 20363505]
27. Murie C, Woody O, Lee AY, Nadon R. Comparison of small n statistical tests of differential expression applied to microarrays. *BMC Bioinformatics*. 2009; 10:45. [PubMed: 19192265]
28. Rodbard D. A semilogarithmic scale for glucose provides a balanced view of hyperglycemia and hypoglycemia. *J Diabetes Sci Technol*. 2009; 3(6):1395–1401. [PubMed: 20144394]
29. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. *Blood*. 1998; 92(10):3780–3792. [PubMed: 9808572]
30. Foreman JE, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor- β/δ (PPAR β/δ) inhibits cell growth in a mouse mammary gland cancer cell line. *Cancer Lett*. 2010; 288:219–225. [PubMed: 19660859]
31. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. *Nature protocols*. 2006; 1(5):2315–2319.
32. Chang WC, Everley LC, Pfeiffer GR 2nd, Cooper HS, Barusevicius A, Clapper ML. Sulindac sulfone is most effective in modulating β -catenin-mediated transcription in cells with mutant APC. *Ann N Y Acad Sci*. 2005; 1059:41–55. [PubMed: 16382042]
33. Shureiqi I, Jiang W, Zuo X, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR- δ to induce apoptosis in colorectal cancer cells. *Proc Natl Acad Sci U S A*. 2003; 100(17):9968–9973. [PubMed: 12909723]
34. Ouyang N, Williams JL, Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR) δ expression in APC(min/+) mice proportionally to their

- tumor inhibitory effect: Implications for the role of PPAR δ in carcinogenesis. *Carcinogenesis*. 2006; 27(2):232–239. [PubMed: 16141240]
35. Yoshinaga M, Taki K, Somada S, et al. The Expression of Both Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 in Tissues Is Associated with Poor Prognosis in Colorectal Cancer Patients. *Dig Dis Sci*. 2011; 56(4):1194–1200. [PubMed: 20824502]
 36. Su W, Necela BM, Fujiwara K, et al. The high affinity peroxisome proliferator-activated receptor- γ agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. *Int J Cancer*. 2008; 123(5):991–997. [PubMed: 18546290]
 37. Niho N, Takahashi M, Shoji Y, et al. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR γ ligand. *Cancer Sci*. 2003; 94(11):960–964. [PubMed: 14611672]
 38. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. *Gastroenterology*. 2003; 124(2):361–367. [PubMed: 12557142]
 39. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPAR γ , is aberrantly expressed in colonic cancers. *Carcinogenesis*. 1998; 19(1):49–53. [PubMed: 9472692]
 40. Jansson EA, Are A, Greicius G, et al. The Wnt/ β -catenin signaling pathway targets PPAR γ activity in colon cancer cells. *Proc Natl Acad Sci U S A*. 2005; 102(5):1460–1465. [PubMed: 15665104]
 41. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPAR γ enhance colon polyp formation. *Nat Med*. 1998; 4(9):1058–1061. [PubMed: 9734400]
 42. Matthiessen MW, Pedersen G, Albrektzen T, Adamsen S, Fleckner J, Brynskov J. Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. *Scand J Gastroenterol*. 2005; 40(2):198–205. [PubMed: 15764152]
 43. Bogazzi F, Ultimieri F, Raggi F, et al. Peroxisome proliferator activated receptor γ expression is reduced in the colonic mucosa of acromegalic patients. *J Clin Endocrinol Metab*. 2002; 87(5):2403–2406. [PubMed: 11994396]
 44. Bogazzi F, Ultimieri F, Raggi F, et al. Changes in the expression of the peroxisome proliferator-activated receptor γ gene in the colonic polyps and colonic mucosa of acromegalic patients. *J Clin Endocrinol Metab*. 2003; 88(8):3938–3942. [PubMed: 12915690]
 45. Hollingshead HE, Borland MG, Billin AN, Willson TM, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor- β/δ (PPAR β/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. *Carcinogenesis*. 2008; 29(1):169–176. [PubMed: 17893232]
 46. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. *Nat Med*. 2004; 10(5):481–483. [PubMed: 15048110]
 47. Marin HE, Peraza MA, Billin AN, et al. Ligand activation of peroxisome proliferator-activated receptor β/δ (PPAR β/δ) inhibits colon carcinogenesis. *Cancer Res*. 2006; 66(8):4394–4401. [PubMed: 16618765]
 48. Wang D, Wang H, Guo Y, et al. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. *Proc Natl Acad Sci U S A*. 2006; 103(50):19069–19074. [PubMed: 17148604]
 49. Zuo X, Peng Z, Moussalli MJ, et al. Targeted genetic disruption of peroxisome proliferator-activated receptor- δ and colonic tumorigenesis. *J Natl Cancer Inst*. 2009; 101(10):762–767. [PubMed: 19436036]
 50. Yang L, Zhou ZG, Zheng XL, et al. RNA Interference Against Peroxisome Proliferator-Activated Receptor δ Gene Promotes Proliferation of Human Colorectal Cancer Cells. *Dis Colon Rectum*. 2008; 51(3):318–328. [PubMed: 18214615]
 51. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPAR δ decreases the tumorigenicity of human colon cancer cells. *Proc Natl Acad Sci U S A*. 2001; 98(5):2598–2603. [PubMed: 11226285]

Figure 1.

Expression of PPAR β/δ protein and mRNA is lower in human colon tumors compared to matched control tissue. (A) Representative quantitative western blot of PPAR β/δ , PPAR γ and CYCLIN D1 expression in normal colon or rectal tissue and colon or rectal tumors. A total of nineteen colon tumors or matched control colon tissue from the same patient, or fourteen rectal tumors or matched rectal tissue from the same patient were examined. + = positive control: lysate from COS1 cells transfected with human PPAR β/δ , or in vitro translated human PPAR γ 1. Values were normalized to ACTIN. Values represent the mean $\pm$ S.E.M. from all independent samples. Values with different superscripts are significantly different at $P < 0.05$. (B) Quantitative realtime PCR was performed to measure expression of mRNA encoding PPAR β/δ . Normalized values were calculated from the independent samples described in (A) and represent the mean $\pm$ S.E.M. from all independent samples. Comparisons were made between normal tissue and both colon and rectal tumors combined (left panel), or by tumor type (right panel). (C) The ratio of relative PPAR β/δ mRNA between tumor and matched control tissue was calculated and log transformed. *Statistically lower in tumors as compared to matched tissue control, $P < 0.05$.

Figure 2.

Expression of PPAR β/δ and PPAR γ protein and mRNA in colon and colon tumors from wild-type and *APC*^{+/Min-FCCC} mice. (A) Tissue extracts were prepared from colon (normal and tumor) from wild-type or *APC*^{+/Min-FCCC} mice fed either a control diet or one containing sulindac as described in the Materials and Methods. Representative western blots were performed to measure expression of PPAR β/δ , PPAR γ or CYCLIN D1 and normalized to ACTIN. + = positive control: lysate from COS1 cells transfected with mouse PPAR β/δ expression vector or, in vitro translated mouse PPAR γ 1. A total of nine independent samples per group were examined. Arrow indicates immunoreactive band for PPAR γ 1 (B) Quantitative realtime PCR was performed to measure expression of mRNA encoding *Pparβ/δ* or *Pparγ1* and normalized to *Gapdh* mRNA. Normalized values were calculated from the nine independent samples described in (A) and represent the mean $\pm$ S.E.M. from all independent samples. Values within a row with different superscripts are significantly different at *P* < 0.05.

Figure 3.

Effect of ligand activation of PPAR β/δ on markers of apoptosis in human colon cancer cell lines following induction of apoptosis by NSAIDs or hydrogen peroxide. Human colon cancer cell lines (RKO-wild-type APC/ β -CATENIN, DLD1 and HT29-constitutively active APC/ β -CATENIN) were cultured with the indicated concentrations of GW0742 and 800 μ M indomethacin (upper left panel), 150 μ M sulindac (upper right panel), 160 μ M sulindac sulfide (lower left panel), or 0.5 mM hydrogen peroxide (lower right panel). For indomethacin, sulindac and sulindac sulfide treatment, cells were cultured for 24 h and whole cell lysates prepared at the end of this treatment period. For hydrogen peroxide treatment, cells were cultured for 4 h and whole cell lysates prepared at the end of this treatment period. Cells cultured without the NSAID, hydrogen peroxide or GW0742 served

as a negative control (–). Cells cultured without the NSAID, hydrogen peroxide or GW0742 but in the presence of 2 μ M staurosporine for 5 h served as a positive control (+). Expression of uncleaved (U) and cleaved (C) PARP and 14-3-3 ϵ was measured by quantitative western blots. The immunoreactive signals for uncleaved PARP, cleaved PARP or 14-3-3 ϵ were normalized to the immunoreactive signals for LDH. PARP expression is shown as the ratio of the normalized values of cleaved/uncleaved PARP and is presented as the mean $\pm$ S.E.M. Normalized 14-3-3 ϵ expression is shown as the fold change as compared to control cells for each respective group and is presented as the mean $\pm$ S.E.M.. A total of at least three independent samples were examined for each treatment except for the negative and positive controls. *Significantly different from control (NSAID-treated without GW0742) at $P = 0.05$. ND=cleaved PARP not detected.

Figure 4.

Modulation of hydrogen peroxide-induced apoptosis and cell viability following ligand activation of PPAR β/δ . (A) RKO, (B) DLD1, or (C) HT29 human colon cancer cell lines were cultured to approximately 80% confluency and then pretreated for 1 h with either 0.02% DMSO (control), or GW0742 (0.1, 1.0, and 10 μ M). Cells were then treated for 4 h in medium containing either 0.0, 0.5, or 5.0 mM hydrogen peroxide in the presence of the indicated concentration of GW0742. Apoptosis and viability was determined by flow cytometry after labeling with propidium iodide and a FITC-labeled anti-annexin V antibody. Viable cells were defined as the percentage of cells that were annexin V-negative and PI-negative. Early apoptosis was defined as the percentage of cells that were annexin V-positive and PI-negative, and late apoptosis/necrosis was defined as the percentage of cells that were annexin V-negative and PI-positive or annexin V-positive and PI-positive. The

percentage of cells within each category was calculated as described in the Materials and Methods. Values represent the mean $\pm$ S.E.M. from at least three independent samples. #Significantly different from untreated control at $P = 0.05$. *Significantly different from respective control at $P = 0.05$.

Figure 5.

Characterization of stable human colon cancer cell lines over-expressing PPARβ/δ. (A) Human colon cancer cell lines (RKO, DLD1 and HT29) were used to generate stable cell lines over-expressing PPARβ/δ and eGFP as described in Materials and Methods. Representative photomicrographs using phase contrast microscopy (upper panels) or fluorescence (lower panels) of control (parent cell line), cells stably expressing the Migr1-empty vector (Migr1), or cells stably expressing PPARβ/δ (hPPARβ/δ). (B) Quantitative western blots were performed to measure expression of PPARβ/δ in control (parent cell line), cells stably expressing the Migr1-empty vector (Migr1), or cells stably expressing PPARβ/δ (hPPARβ/δ). Values represent PPARβ/δ expression normalized to LDH control as compared to control cells. (C) Quantitative realtime PCR was performed to determine the effect of ligand activation of PPARβ/δ by GW0742 in control (parent cell line), cells stably expressing the Migr1-empty vector (Migr1), or cells stably expressing PPARβ/δ (hPPARβ/δ). Normalized *ADRP* or *ANGPTL4* mRNA were measured as markers of PPARβ/δ transcriptional activity. *Significantly different from respective control at $P < 0.05$.

Figure 6.

Effect of ligand activation of PPAR β/δ on colony formation in human colon cancer cell lines over-expressing PPAR β/δ . Control (parent RKO cell line), RKO cells stably expressing the Migr1-empty vector (Migr1), or RKO cells stably expressing PPAR β/δ (Migr1-hPPAR β/δ) were plated at 300 cells per well. After allowing the cells to adhere for 24 h, cells were treated with medium containing either: 0 (DMSO control), 0.1, 1.0 or 10 μ M GW0742. Plating efficiency (%) was 32 ± 1 , 48 ± 6 , and 55 ± 1 for parent RKO, Migr1 and Migr1-hPPAR β/δ cells, respectively. The surviving fraction was calculated after colony number was quantified using Image J software (version 1.37, National Institutes of Health, Bethesda, MD). The surviving fraction is presented as the mean $\pm$ S.E.M.. *Significantly different from control, $P < 0.05$. #Significantly different from control, $P < 0.01$.

†Significantly different from control, $P < 0.001$.

Figure 7.

Effect of ligand activation of PPAR β/δ on colony formation in human colon cancer cell lines over-expressing PPAR β/δ . Control (parent DLD1 cell line), DLD1 cells stably expressing the Migr1-empty vector (Migr1), or DLD1 cells stably expressing PPAR β/δ (Migr1-hPPAR β/δ) were plated at 400 cells per well. After allowing the cells to adhere for 8 h, cells were treated with medium containing either: 0 (DMSO control), 0.1, 1.0 or 10 μ M GW0742. Plating efficiency (%) was 20 ± 1 , 27 ± 2 , and 24 ± 2 for parent DLD1, Migr1 and Migr1-hPPAR β/δ cells, respectively. The surviving fraction was calculated after colony number was quantified using Image J software (version 1.37, National Institutes of Health, Bethesda, MD). The surviving fraction is presented as the mean $\pm$ S.E.M.. #Significantly different from control, $P < 0.01$.

Figure 8.

Effect of ligand activation of PPAR β/δ on colony formation in human colon cancer cell lines over-expressing PPAR β/δ . Control (parent HT29 cell line), HT29 cells stably expressing the Migr1-empty vector (Migr1), or HT29 cells stably expressing PPAR β/δ (Migr1-hPPAR β/δ) were plated at 600 cells per well. After allowing the cells to adhere for 8 h, cells were treated with medium containing either: 0 (DMSO control), 0.1, 1.0 or 10 μ M GW0742. Plating efficiency (%) was 20 ± 1 , 25 ± 2 , and 27 ± 2 for parent HT29, Migr1 and Migr1-hPPAR β/δ cells, respectively. The surviving fraction was calculated after colony number was quantified using Image J software (version 1.37, National Institutes of Health, Bethesda, MD). The surviving fraction is presented as the mean $\pm$ S.E.M.. #Significantly different from control, $P < 0.01$. [†]Significantly different from control, $P < 0.001$.

Table 1

Demographics of colon and rectal adenocarcinomas

Tumor type	Age		Sex		
	N	Mean $\pm$ SD	Range	Male	Female
Colon	19	64.8 $\pm$ 16.6	33–86	7	10
Rectal	14	58.8 $\pm$ 13.8	33–85	4	10
					2
					0